Skip to main content

Astrazeneca Plc(AZN-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low188.00
Day High190.59
Open:188.91
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus
Osimertinib Cements Lead in EGFR Lung Cancer as AstraZeneca Updates Key Phase 3 Trial
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca’s Ultomiris Hits Phase III Mark in Rare Kidney Disease
AstraZeneca’s OBERON COPD Trial Reaches Completion, Setting Up a Key Catalyst for AZN
AstraZeneca Nears Key COPD Milestone With Phase III Tozorakimab Trial
AstraZeneca Completes Early Imaging Study in Crohn’s Disease, Nudging Pipeline Hopes for AZN
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca (AZN) Gets a Buy from Citi
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM
ESPERANZA Update: Real-World Data Study Could Broaden AstraZeneca’s T-DXd Cancer Opportunity
J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Buy from Goldman Sachs
AstraZeneca Completes Early Obesity Trial for AZD6234, Nudging Long-Term Growth Hopes
AstraZeneca Reports Strong Liver Cancer Results for Imfinzi–Imjudo Combo in EMERALD-3 Trial
AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes
AstraZeneca (AZN) Gets a Buy from J.P. Morgan
Jefferies Sticks to Its Buy Rating for AstraZeneca (AZN)

Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.